CytomX Therapeutics (CTMX) Other Non Operating Income (2014 - 2026)
CytomX Therapeutics' (CTMX) quarterly Other Non Operating Income came in at -$7000.0 in Q1 2026, down 163.64% YoY from $11000.0 in Q1 2025, and up 98.2% on a QoQ basis from -$388000.0 in Q4 2025.
CytomX Therapeutics (CTMX) Other Non Operating Income (2014 - 2026) Analysis & Trends
CytomX Therapeutics (CTMX) has 13 years of Other Non Operating Income data on file, last reported at -$7000.0 in Q1 2026.
- Quarterly Other Non Operating Income fell 163.64% year-over-year to -$7000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$373000.0 (down 2094.12% YoY) and the FY2025 annual result came in at -$355000.0, down 834.21% from the prior year.
- Other Non Operating Income grew to -$7000.0 in Q1 2026, from -$388000.0 in the prior quarter.
- In the past five years, Other Non Operating Income ranged from a high of $296000.0 in Q2 2022 to a low of -$388000.0 in Q4 2025.
- A 5-year average of -$5352.9 and a median of $1000.0 in 2022 frame the typical range for Other Non Operating Income.
- The widest YoY moves for Other Non Operating Income: up 950.0% in 2025, down 1942.11% in 2025.
- Tracing CTMX's Other Non Operating Income over 5 years: stood at $1000.0 in 2022, then surged by 800.0% to $9000.0 in 2023, then slumped by 311.11% to -$19000.0 in 2024, then plunged by 1942.11% to -$388000.0 in 2025, then jumped by 98.2% to -$7000.0 in 2026.
- The last three Other Non Operating Income figures came in at -$7000.0 (Q1 2026), -$388000.0 (Q4 2025), and $5000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | CytomX Therapeutics | 732.14 Mn | 401.86 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 18,000.00 |
| Mar 31, 2026 | -7,000.00 |
| Dec 31, 2025 | -388,000.00 |
| Sep 30, 2025 | 5,000.00 |
| Jun 30, 2025 | 17,000.00 |
| Mar 31, 2025 | 11,000.00 |
| Dec 31, 2024 | -19,000.00 |
| Sep 30, 2024 | -7,000.00 |
| Jun 30, 2024 | -2,000.00 |
| Mar 31, 2024 | -11,000.00 |
| Dec 31, 2023 | 9,000.00 |
| Sep 30, 2023 | -7,000.00 |
| Jun 30, 2023 | -47,000.00 |
| Mar 31, 2023 | 15,000.00 |
| Dec 31, 2022 | 1,000.00 |
| Sep 30, 2022 | 30,000.00 |
| Jun 30, 2022 | 296,000.00 |
| Mar 31, 2022 | 13,000.00 |
| Dec 31, 2021 | 7,000.00 |
| Sep 30, 2021 | -13,000.00 |